Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ATG-022
i
Other names:
ATG-022
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Antengene
Drug class:
CLDN18.2-targeted antibody-drug conjugate
Related drugs:
‹
SOT102 (5)
AZD0901 (4)
EO-3021 (4)
BMS-986476 (3)
IBI-343 (0)
MK-1200 (0)
RC118 (0)
SHR-A1904 (0)
TQB2103 (0)
SOT102 (5)
AZD0901 (4)
EO-3021 (4)
BMS-986476 (3)
IBI-343 (0)
MK-1200 (0)
RC118 (0)
SHR-A1904 (0)
TQB2103 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
CLDN18.2 underexpression
Gastric Cancer
CLDN18.2 underexpression
Gastric Cancer
ATG-022
Sensitive: D – Preclinical
ATG-022
Sensitive
:
D
ATG-022
Sensitive: D – Preclinical
ATG-022
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login